Drug development companies have developed innovative approaches to drug formulation to avoid or reduce the adverse events that accompany pain management drugs. Iroko Pharmaceuticals has been building a portfolio of low dose Non Steroidal Anti Inflammatory Drugs. It presented data from a Phase 3 trial of its osteoarthritis drug SoluMatrix Meloxicam at the Annual European […]
The U.S. Food and Drug Administration has approved Iroko Pharmaceuticals’ drug Zorvolex to treat mild to moderate acute pain in adults, according to a company statement. It’s a milestone for the Philadelphia drug developer. which has been working on a new formulation to conform with the FDA’s Non Steroidal Anti Inflammatory Drug requirements issued in […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
A pharmaceutical company has tapped Novartis (NYSE:NVS) and Pfizer (NYSE:PFE) for chief medical officer and general counsel positions. Dr. Clarence L. Young will serve as chief medical officer and will lead Iroko Pharmaceuticals’ clinical programs for the company’s investigational, nonsteroidal anti-inflammatory drugs. He previously worked at Novartis as global head of targeted therapies and integrated […]